Table 1. Activity of m276-SL-PBD across 26 Ewing sarcoma, rhabdomyosarcoma, osteosarcomas and neuroblastoma models.
KM Med = Kaplan-Meier estimate of median time-to-event, EFS T – C = difference in median time-to-event of treatment group compared to control, EFS T/C = ratio of median time-to-event of treatment group compared to control group.
| Cancer Type | Model | Agent | N | KM med (days) | EFS T - C (days) | EFS T/C | p-value Gehan-Wilcoxon | minRTV mean±SD | minRTV p-value | Objective Response Measure+ |
|---|---|---|---|---|---|---|---|---|---|---|
| Ewing sarcoma | ES-1‡ | control | 10 | 9.1 | 3.450±0.805 | |||||
| mCD276- SL-PBD |
10 | > 105 | > 95.9 | > 11.49 | p < 0.001 | 0.025 ±0.070 |
p < 0.001 | MCR | ||
| ES-6‡ | control | 10 | 15.5 | 2.248 ±0.762 |
||||||
| mCD276- SL-PBD |
10 | > 41 | > 25.5 | > 2.64 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | CR | ||
| SK- NEP-1‡ |
control | 10 | 7.6 | 3.521 ±1.254 |
||||||
| mCD276- SL-PBD |
10 | > 111 | > 103.4 | > 14.53 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
|
Alveolar RMS (Fusion+ RMS) |
Rh-30 | control | 10 | 17.2 | 2.033 ±0.558 |
|||||
| mCD276- SL-PBD |
10 | > 126 | > 108.8 | > 7.31 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
| Rh-41 | control | 10 | 12.9 | 2.269 ±0.376 |
||||||
| mCD276- SL-PBD |
10 | > 105 | > 92.1 | > 8.15 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
|
Embryonal RMS (Fusion-RMS) |
Rh-18 | control | 10 | 15.0 | 1.873 ±0.239 |
|||||
| mCD276- SL-PBD |
10 | > 119 | > 104 | > 7.91 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
| Rh-36 | control | 10 | 4.7 | 8.584 ±2.174 |
||||||
| mCD276- SL-PBD |
10 | > 105 | > 100.3 | > 22.14 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
| Wilms tumor | KT-10 | control | 10 | 13.5 | 2.103 ±0.372 |
|||||
| mCD276- SL-PBD |
10 | > 98 | > 84.5 | > 7.26 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
| KT-11 | control | 10 | 13.3 | 2.123 ±0.385 |
||||||
| mCD276- SL-PBD |
10 | > 105 | > 91.7 | > 7.9 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
| Osteosarcoma | OS-1 | control | 9 | 32.3 | 1.556 ±0.244 |
|||||
| mCD276- SL-PBD |
10 | > 76 | > 43.7 | > 2.36 | p < 0.001 | 0.076 ±0.116 |
p < 0.001 | CR | ||
| OS-2 | control | 10 | 16.3 | 1.455 ±0.186 |
||||||
| mCD276- SL-PBD |
10 | > 69 | > 52.7 | > 4.23 | p < 0.001 | 0.000 ±0.000 |
p < 0.001 | MCR | ||
| OS-9 | control | 10 | 15.3 | 2.077 ±0.278 |
||||||
| mCD276- SL-PBD |
10 | > 26 | > 10.7 | > 1.7 | p < 0.001 | 0.442 ±0.162 |
p < 0.001 | SD | ||
| OS-31 | control | 10 | 20.2 | 1.853 ±0.291 |
||||||
| mCD276- SL-PBD |
10 | > 62 | > 41.8 | > 3.07 | p < 0.001 | 0.071 ±0.119 |
p < 0.001 | CR | ||
| OS-33 | control | 10 | 17.8 | 1.717 ±0.404 |
||||||
| mCD276- SL-PBD |
10 | > 62 | > 44.2 | > 3.48 | p < 0.001 | 0.000± 0.000 |
p < 0.001 | MCR |
| Cancer Type | Model | Agent | N | KM med (days) | EFS T - C (days) | EFS T/C | minRTV mean±SD | Objective Response Measure+ |
|---|---|---|---|---|---|---|---|---|
| Neuroblastoma◊ | COG-N- 415x |
control | 2 | 6.2 | 2.052±0.162 | |||
| mCD276- SL-PBD |
2 | 46.9 | 40.7 | 7.53 | 0.000±0.000 | MCR | ||
| COG-N- 421x |
control | 2 | 21.5 | 1.136±0.179 | ||||
| mCD276- SL-PBD |
2 | > 101 | > 79.5 | > 4.69 | 0.000±0.000 | MCR | ||
| COG-N- 452x |
control | 2 | 17.8 | 1.069±0.062 | ||||
| mCD276- SL-PBD |
2 | > 102 | > 84.2 | > 5.73 | 0.000±0.000 | MCR | ||
| COG-N- 453x |
control | 2 | 9.8 | 2.304±0.323 | ||||
| mCD276- SL-PBD |
2 | > 100 | > 90.2 | > 10.23 | 0.000±0.000 | MCR | ||
| COG-N- 480x |
control | 2 | 12.7 | 1.623±0.498 | ||||
| mCD276- SL-PBD |
2 | > 108 | > 95.3 | > 8.54 | 0.000±0.000 | MCR | ||
| COG-N- 496x |
control | 2 | 9.1 | 1.742±0.278 | ||||
| mCD276- SL-PBD |
2 | > 43 | > 33.9 | > 4.75 | 0.175±0.084 | PR | ||
| COG-N- 519x |
control | 2 | 12.9 | 1.529±0.321 | ||||
| mCD276- SL-PBD |
2 | > 101 | > 88.1 | > 7.82 | 0.021±0.030 | CR | ||
| COG-N- 426x-Felix- PDX |
control | 2 | 11.8 | 1.006±0.094 | ||||
| mCD276- SL-PBD |
2 | > 26 | > 14.2 | > 2.2 | 0.000±0.000 | CR | ||
| NB-1643‡ | control | 2 | 12.4 | 1.016±0.002 | ||||
| mCD276- SL-PBD |
2 | > 50 | > 37.6 | > 4.03 | 0.122±0.004 | PR | ||
| NB-1691‡ | control | 2 | 7.3 | 1.790±0.119 | ||||
| mCD276- SL-PBD |
2 | 28.8 | 21.5 | 3.95 | 1.831±0.485 | PD1 | ||
| NB-Ebc1‡ | control | 2 | 6.8 | 2.888±0.698 | ||||
| mCD276- SL-PBD |
2 | > 102 | > 95.2 | > 15.02 | 0.000±0.000 | MCR | ||
| NB-SD‡ | control | 2 | 19.1 | 1.108±0.007 | ||||
| mCD276- SL-PBD |
2 | > 64 | > 44.9 | > 3.36 | 0.094±0.034 | PR |
◊
Note: Neuroblastoma experiments had N=2, thus p-values are not reported.
‡
cell line-derived xenograft models.